Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears Trinity's AMAX haemostasis analyser:

This article was originally published in Clinica

Executive Summary

Trinity Biotech has received US FDA marketing clearance for its AMAX Destiny haemostasis analyser, an instrument which the company claims allows it to target an additional segment of the $700m haemostasis market. The system offers high-end technology on a small, low cost platform, giving smaller clinical laboratories the ability to process haemostasis tests formerly offered only in large reference laboratories, says the Bray, Ireland-based firm. The product offers the flexibility to perform both optical and mechanical clot, chromogenic and immunoturbidimetric- based assays simultaneously.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts